All In Biotech

Drug Trial Radar · NCT05364021

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Mar 3, 2022

Primary completion

Nov 16, 2023

Study completion Nov 20, 2023

Sponsor

Lead sponsor
Longboard PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Conditions

  • Developmental and Epileptic Encephalopathy
  • Dravet Syndrome
  • Lennox Gastaut Syndrome

Interventions

  • LP352Drug

    LP352 administered three times daily, orally or through G-tube

  • PlaceboDrug

    Matching placebo for LP352 administered three times daily, orally or through G-tube

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent Adverse EventsTime frame: Baseline up to Day 75
  2. Columbia-Suicide Severity Rating Scale (C-SSRS) ResponseTime frame: Baseline up to Day 75
  3. Patient Health Questionnaire-9 Total Score and Question 9 ScoreTime frame: Baseline up to Day 75
  4. Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Treatment PeriodTime frame: Baseline up to Day 75
  5. Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Maintenance PeriodTime frame: Baseline up to Day 75

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona - Health Sciences Center

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Rancho Los Amigos National Rehabilitation Center (RLANRC)

    Downey, California

  • Children's Hospital of Orange County

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • Northwest Florida Clinical Research Group

    Gulf Breeze, Florida

  • University of Miami

    Miami, Florida

  • Advent Health Orlando

    Orlando, Florida

  • Research Institute of Orlando

    Orlando, Florida

  • University of South Florida

    Tampa, Florida

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Consultants in Epilepsy and Neurology

    Boise, Idaho

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Spectrum Health

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Boston Children's Health Physicians LLP

    Hawthorne, New York

  • New York University Langone Hospital - Long Island

    Mineola, New York

  • Northwell Health

    New York, New York

  • Northeast Regional Epilepsy Group

    Staten Island, New York

  • OnSite Clinical Solutions LLC

    Charlotte, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Providence Neurological Specialties-East

    Portland, Oregon

  • Child Neurology Consultants of Austin

    Austin, Texas

  • Austin Epilepsy Care Center

    Austin, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Washington Valley Medical Center

    Renton, Washington

  • Royal Brisbane Women's Hospital

    Herston, Queensland, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Monash Children's Hospital, Monash Health

    Clayton, Victoria, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.